SCHEMBL26698252

SCHEMBL26698252

Nc1cccc2c(-c3cn[nH]c3)c[nH]c12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IMPDH2 P12268 1/20 0.63
▸ CLK1 P49759 3/20 0.53
▸ CDK5 Q00535 3/20 0.53
▸ CDK5R1 Q15078 3/20 0.53
▸ DYRK1A Q13627 7/20 0.45
▸ AKT1 P31749 1/20 0.41
▸ AKT2 P31751 1/20 0.41
▸ AURKA O14965 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ INCENP Q9NQS7 1/20 0.40
▸ TPX2 Q9ULW0 1/20 0.40
▸ GSK3B P49841 4/20 0.39
▸ NFATC1 O95644 1/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ CHEK2 O96017 1/20 0.39
▸ MAPK8 P45983 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ FEN1 P39748 2/20 0.38
▸ LRRK2 Q5S007 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500355 0.78 IMPDH2 (1.00) IMPDH2CLK1CDK5CDK5R1DYRK1A
SCHEMBL30771213 0.77 HTT (0.45) IMPDH2AKT1AKT2PIM1CCNT1
SCHEMBL20468195 0.74 AKT2 (0.55) AKT1AKT2AURKAAURKBINCENP
SCHEMBL16697582 0.73 IMPDH2 (0.59) IMPDH2AKT1AKT2GSK3BCHEK1
SCHEMBL29563848 0.73 IMPDH2 (0.59) IMPDH2AKT1AKT2GSK3BCHEK1
SCHEMBL26912973 0.72 CSNK2A2 (0.41) DYRK1AAKT1AKT2AURKAAURKB
SCHEMBL17179567 0.71 IMPDH2 (0.57) IMPDH2CLK1CDK5CDK5R1DYRK1A
SCHEMBL19832095 0.70 AURKA (0.63) CDK5DYRK1AAURKAAURKBINCENP
SCHEMBL29869736 0.70 AURKA (0.63) CDK5DYRK1AAURKAAURKBINCENP
SCHEMBL26912618 0.70 AURKA (0.38) CLK1CDK5CDK5R1DYRK1AAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-11-13 — — US disclosed
EP-4532484-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-04-09 — — EP disclosed
CN-119173509-A ROCK inhibitors and uses thereof 迪哲(江苏)医药股份有限公司 2024-12-20 — — CN disclosed
WO-2023226965-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF ROCK1, ROCK2, RHOA IMPDH2 2191/4885CLK1 2496/4885CDK5 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback